Karen M Meagher

Dr. Karen M Meagher

Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 April 2020 in Mayo Clinic Proceedings
Verified
Journal Article
Closed access
Karen M MeagherKaren M Meagher
Karen M Meagher
Nathan W. CumminsNathan W. Cummins
Nathan W. Cummins
ABAdil E. Bharucha
Adil E. Bharucha
ABAndrew D. Badley
Andrew D. Badley
LCLinda L. Chlan
Linda L. Chlan
RWR. Scott Wright
R. Scott Wright

28 June 2023 in The American Journal of Bioethics
Verified
Journal Article
Closed access
SCSamantha A. Chipman
Samantha A. Chipman
Karen M MeagherKaren M Meagher
Karen M Meagher
ABAmelia K. Barwise
Amelia K. Barwise
25.6 Million people in the United States have Limited English Proficiency (LEP), defined as insufficient ability to read, write, or understand English. We will (1) Delineate the merits of approaching language as a social determinant of health, (2) highlight pertinent public health values and guidelines which are most relevant to the plight of populations with LEP and (3) Use the COVID-19 pandemic as an example of how a breakdown in public health ethics values created harm for populations and patients with LEP. We define a framework to tease out public health responsibilities given some populations' limited proficiency in a society's predominant language. The American Public Health Association (APHA) public health ethics core values serve as a framework to interrogate current practices. We use the COVID-19 case to illustrate gaps between health policy and healthcare disparities experienced by populations with LEP.

23 February 2025 in The American Journal of Bioethics
Verified
Journal Article
Open access
MAMegan A. Allyse
Megan A. Allyse
PAPreya Agam
Preya Agam
YBYvonne Bombard
Yvonne Bombard
RFRoel Feys
Roel Feys
MHMcKenna Horstmann
McKenna Horstmann
JYJane Q. Yap
Jane Q. Yap
Despite considerable scientific progress and the evolution of regulatory pathways to ensure safety and efficacy, US healthcare continues to see increasing health disparities. This suggests that clinical translation in of itself cannot be the only measure of its own success, especially when the most marginalized patients, are neglected in the development and implementation of medical innovations. This raises the question of whether a system that is narrowly focused on technical achievement can meet the moral obligations of medicine and public health. We argue that traditional technocratic standards are failing to integrate normative considerations into biomedical translation. What is needed is a translational domain that moves beyond safety and efficacy toward anticipating how proposed technologies will be effective in society as it exists. We propose an additional metric of success: translational justice.

1 February 2020 in Mayo Clinic Proceedings
Verified
Journal Article
Open access
Karen M MeagherKaren M Meagher
Karen M Meagher
MAMegan A. Allyse
Megan A. Allyse
ZMZubin Master
Zubin Master
Richard SharpRichard Sharp
Richard Sharp
In November 2018, the announcement that genetically edited human embryos had been used for reproductive purposes caused international uproar; many observers argued that editing the human germline was unethical, particularly given the early stage of the science and the absence of appropriate oversight. We provide an overview of the implications of these events, focusing on the relevant ethical considerations for physicians addressing patient questions and concerns. The editing of the human germline for reproductive purposes should be understood against an historic backdrop of clinical research in assisted reproduction, as well as other exemplars of translational investigation. An important question raised by our growing capacity to genetically alter human embryos is how to understand the implicit social contract between science and society. To ensure that translational research continues to enjoy the historic trust placed in scientists and research organizations, it is critical that scientific and health care institutions proactively engage governments, patient advocacy organizations, and the general public in the formation of policies that guide gene editing.

1 January 2021 in Mayo Clinic Proceedings
Verified
Journal Article
Closed access
MLMaria I Lapid
Maria I Lapid
Karen M MeagherKaren M Meagher
Karen M Meagher
HGHannah C. Giunta
Hannah C. Giunta
BCBart L. Clarke
Bart L. Clarke
YOYves Ouellette
Yves Ouellette
RWR. Scott Wright
R. Scott Wright

1 October 2024 in Journal of Empirical Research on Human Research Ethics
Verified
Journal Article
Closed access
Karen M MeagherKaren M Meagher
Karen M Meagher
SWSara Watson
Sara Watson
LKLia Kaz
Lia Kaz
SCShawneequa Callier
Shawneequa Callier
APAnya E.R. Prince
Anya E.R. Prince
RCR. Jean Cadigan
R. Jean Cadigan
We demonstrate the fruitfulness of using card sort activities as an engagement method by detailing community consultation for ethical, legal, and social implications of sociogenomics. Readers are provided with a user-guide for card sort engagement through: (1) an overview of the card sort activity and its merits for engagement, (2) detailed methods of sorting for values-elicitation and prioritization goals, and (3) strategies to design this approach for other participatory research designs. Our intent is to add to meaningful exchanges between community engaged researchers and empirical bioethicists.